

NEWS RELEASE
For immediate use

19 October 2023

Conclusio announces new clinical research and innovation advisor

Leading market access and health transformation agency, Conclusio, is pleased to announce the engagement of Professor William Alazawi as an advisor in Clinical Research and Innovation. This will further strengthen Conclusio's core team and panel of NHS subject matter experts as it expands its portfolio offer.

William Alazawi has a rich clinical and research background. He is Professor of Hepatology and a Consultant Hepatologist, based at Barts Health and Queen Mary University London. Professor Alazawi is also an internationally recognised academic and leads a thriving research group, which studies the science that underlies liver disease.

His engagement continues to build on Conclusio's service portfolio as it develops its new clinical service and engagement offering and expands its client-base in the Pharmaceutical and Life Sciences Sector.

Conclusio Managing Director and Founder, **James Roach** says

"Professor Alazawi's clinical research expertise will make a real difference to how we work with Industry. With his input, our market access offer now covers all stages of development; from research to market- entry and uptake."

William's areas of focus within Conclusio will be its client's service and pathway development projects as well as advising on outcomes monitoring, clinical and patient engagement and future pipelining of products and services.

James Roach adds

"As Conclusio extends its support and access programmes across specialist medicines and pathways it's critical our clients have access to insights from some of the UK's most exciting and innovative clinical leaders. Professor Alazawi's engagement is a real coup for Conclusio and will support our growth plans and, more critically, ensure our clients continue to have access to subject matter experts and clinical innovators."

Responding to his new advisory role, **Professor Alazawi** says

"I have worked as a doctor in the NHS, mostly as a clinical academic, for over 20 years and I look forward to sharing my experiences as a clinician and as a researcher to bring together a range of stakeholders with an overall goal of improving patient care."

Professor Alazawi's research portfolio ranges from basic science discovery work, epidemiology and through to developing innovative pathways of care and their implementation. He has an interest in the full spectrum of liver disease and research related to liver conditions, with particular focus on Non-Alcoholic Fatty Liver.

More information contact Johnny Skillicorn-Aston

Johnny.skillicornaston@conclusio.co.uk

07501 044322

Brief biography



Professor Alazawi graduated from the MB/PhD Programme in Cambridge in 2003. He conducted his doctorate research in Professor Coleman's laboratory at the MRC Cancer Cell Unit where he studied host-viral interactions in pre-malignant disease. He moved to London to work with Professor Graham Foster where he conducted further studies into innate immune signalling, becoming an NIHR Clinical Lecturer in 2011.

He established his own group in 2013 focusing on Non-Alcoholic Fatty Liver Disease and its progressive fibroinflammatory form, Non-Alcoholic Steatohepatitis or NASH for short. His MRC-funded basic science laboratory team studies immune and metabolic signalling with current focus on single cell techniques, multiorgan inflammation and metabolism.

Professor Alazawi also leads a translational programme of research, studying the epidemiology and natural history of NASH, the diagnostic pathways including the management of abnormal liver tests and novel therapies for NASH. He has won a number of prestigious awards including an Academy of Medical Sciences Starter Grant, the Physician Scientist Fellowship of the European Association for the Liver and a New Investigator Award from the Medical Research Council

He is the NIHR Integrated Academic Training Programme Co-Lead at QMUL, Blizard Institute Lead for Research Impact and Clinical Lead for NAFLD at Barts Health. He is the Chair of the BASL Special Interest Group for NAFLD, a member of the Clinical Advisory Group for the British Liver Trust and Head of Research for LAP Research – a UK charity that focuses on liver and pancreatic disease.

Source: www.qmul.ac.uk/blizard/all-staff/profiles/william-alazawi.html

Notes to Editor

- Conclusio was formed in 2014 by James Roach
- Conclusio is at the forefront of ambitious, impactful service change across the pharmaceutical industry landscape, health, social care, voluntary and academic sectors in the UK and internationally
- www.conclusio.org.uk